Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Fineline Cube Jun 30, 2026
Company Deals

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Fineline Cube Jun 30, 2026
Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Fineline Cube Jun 30, 2026
Company Drug

Sunshine Guojian Pharmaceutical’s SSGJ-608 Files for NMPA Approval in Plaque Psoriasis

Fineline Cube Nov 19, 2024

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, (SHA: 688336) a subsidiary of 3SBio Inc. (HKG: 1530),...

Company Drug

Huahui Health’s Libevitug Earns FDA Breakthrough Designation for Chronic Hepatitis Delta Virus

Fineline Cube Nov 19, 2024

Beijing-based biotech company Huahui Health, specializing in viral hepatitis, hepatology, and oncology, has announced that...

Company Medical Device

Xeltis AG Enrolls First Patient in US Pivotal Trial for aXess with FDA BTD Status

Fineline Cube Nov 19, 2024

Holland-based Xeltis AG has announced the enrollment of the first patient in a US-staged pivotal...

Company Deals

Shanghai Leadingtac Pharmaceutical Secures $13.81 Million in Series A Financing

Fineline Cube Nov 19, 2024

Shanghai Leadingtac Pharmaceutical Co., Ltd., a China-based small molecule drug developer, has announced the successful...

Company Drug

Huadong Medicine’s DR10624 Receives NMPA Approval for MAFLD and MASH Clinical Trials

Fineline Cube Nov 19, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...

Policy / Regulatory

NMPA’s CDE Issues Guidelines for Leveraging Real-World Data in Drug Regulation

Fineline Cube Nov 19, 2024

The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has released...

Company Deals

Biosion Secures Licensing Deal with Aclaris Therapeutics for Global Rights to BSI-045B and BSI-502

Fineline Cube Nov 19, 2024

Biosion, a clinical stage biotech company with operations in Delaware, US, and China, has entered...

Company Deals

Ratio Therapeutics Partners with Novartis on SSTR2 Radiotherapeutic for Cancer

Fineline Cube Nov 19, 2024

US-based Ratio Therapeutics Inc. has entered into a global exclusive licensing and cooperation agreement with...

Company Drug

Huadong Medicine’s HDM1005 Receives FDA Approval for MASH Clinical Study

Fineline Cube Nov 19, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a China-based pharmaceutical company, has announced that it has...

Company Drug

TenNor Therapeutics’ Rifasutenizol Shows High Eradication Rate in H. pylori Phase III Study

Fineline Cube Nov 19, 2024

China-based TenNor Therapeutics has announced positive results from its Phase III clinical study for rifasutenizol...

Company Drug

Beijing Wantai Receives NMPA Clearance for Nine-Valent HPV Vaccine Targeting Male Population

Fineline Cube Nov 19, 2024

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a leading Chinese pharmaceutical company, has...

Company Drug

Hasten Biopharmaceutical Initiates Phase III Clinical Trial for Lerodalcibep in China

Fineline Cube Nov 19, 2024

China-based Hasten Biopharmaceutical Co., Ltd, a comprehensive biopharmaceutical company co-established by CBC Group, has announced...

Company Deals

VelaVigo and Avenzo Therapeutics Ink Global Partnership for Nectin4/TROP2 Bispecific ADC

Fineline Cube Nov 19, 2024

Shanghai-based biotech company VelaVigo, specializing in bispecific/multi-specific antibodies and antibody drug conjugates (ADCs), has announced...

Company Deals

Youjia Biomedical and Yiling Pharmaceutical Collaborate on RNAi Metabolic Disease Treatments

Fineline Cube Nov 19, 2024

China-based Youjia (Hangzhou) Biomedical Technology Co., Ltd, a leading nucleic acid technology developer, has entered...

Company Deals

Grand Pharmaceutical Group Expands Distribution Partnership with Sirtex Medical in China

Fineline Cube Nov 18, 2024

Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced...

Company Deals

Keymed Biosciences Enters Global Licensing Agreement with Platina Medicines for CM336

Fineline Cube Nov 18, 2024

Keymed Biosciences Inc., a China-based biopharmaceutical company (HKG: 2162), has announced a significant licensing agreement...

Company Drug

CanSino Biologics Initiates Phase I Clinical Trial for Freeze-Dried Hib Conjugate Vaccine

Fineline Cube Nov 18, 2024

China-based biopharmaceutical company CanSino Biologics (HKG: 6185) has announced the commencement of a Phase I...

Company Deals

Hangzhou Jiuyuan Gene Engineering Passes HKEX IPO Hearing for Orthopedic Treatments

Fineline Cube Nov 18, 2024

Hangzhou Jiuyuan Gene Engineering Co., Ltd. has announced that it has successfully passed the listing...

Company Deals

NK CellTech Partners with 3SBio to Advance NK Cell Therapy Technology

Fineline Cube Nov 18, 2024

China-based natural killer (NK) cell therapy developer NK CellTech has entered into a strategic partnership...

Company Deals

Shanghai’s Matwings Secures Over $13.8 Million in Series A Financing for AI Protein Design

Fineline Cube Nov 18, 2024

Matwings, an AI-based protein design service provider headquartered in Shanghai, has announced the successful completion...

Posts pagination

1 … 287 288 289 … 688

Recent updates

  • METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company
  • Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China
  • Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline
  • Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications
  • Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.